Related Experiment Video
Updated: Apr 15, 2026
07:08
Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
Published on: February 27, 2018
10.2K
Anxiety in Huntington's Disease
1From the Leicestershire Partnership NHS Trust Huntington's Disease Service, Adult Mental Health Clinical Psychology Department, OSL House, East Link, Meridian Business Park, Leicester, United Kingdom (MD); and the Department of Psychiatry, Leiden University Medical Centre, Leiden, Netherlands (EVD).
The Journal of Neuropsychiatry and Clinical Neurosciences
|March 25, 2015
Summary
Anxiety is a common but under-researched symptom in Huntington's disease (HD). This review found anxiety prevalence ranging from 13-71% in manifest HD, with no significant difference in premanifest carriers.
Area of Science:
- Neuroscience
- Psychiatry
- Genetics
Background:
- Anxiety is a frequent yet under-researched symptom in Huntington's disease (HD).
- Understanding anxiety's prevalence and impact is crucial for patient care in HD.
- Existing research on anxiety in HD is limited, necessitating a comprehensive review.
Purpose of the Study:
- To systematically review the prevalence and characteristics of anxiety in Huntington's disease.
- To explore associations between anxiety and other clinical factors in HD.
- To identify potential interventions for anxiety in HD patients.
Main Methods:
- A systematic review of studies on anxiety in Huntington's disease.
- Analysis of anxiety prevalence in manifest and premanifest HD carriers.
- Examination of correlations between anxiety and depression, suicide risk, quality of life, and disease progression.
Main Results:
- Anxiety prevalence in manifest HD ranged from 13% to 71%.
- No significant difference in anxiety was found between manifest and premanifest HD carriers.
- Anxiety showed associations with depression, suicide, irritability, quality of life, pain, illness beliefs, and coping styles, but not disease progression.
Conclusions:
- Anxiety is a significant concern in Huntington's disease, affecting both manifest and premanifest stages.
- Further research is needed to improve anxiety assessment and develop effective interventions.
- Promising interventions include pharmacological (olanzapine) and psychosocial approaches.
Related Concept Videos
01:18Anxiety: Overview
1.3K
Anxiety is a common mental disorder featuring excessive worry, fear, and apprehension, significantly affecting daily life. People with anxiety disorders experience persistent and intense anxiety, interrupting their everyday functioning.
Individuals with anxiety often experience a range of physical and emotional symptoms, including sweating, trembling, tachycardia, and disturbances in sleep patterns. These symptoms vary in intensity and frequency but are generally disruptive and distressing.
Individuals with anxiety often experience a range of physical and emotional symptoms, including sweating, trembling, tachycardia, and disturbances in sleep patterns. These symptoms vary in intensity and frequency but are generally disruptive and distressing.
1.3K
01:30Generalized Anxiety Disorder
1.2K
Generalized Anxiety Disorder (GAD) is a chronic condition characterized by excessive and uncontrollable worry that persists for at least six months, significantly interfering with daily functioning. Unlike situational anxiety, which arises in response to specific stressors, GAD often occurs without a clear cause. Individuals may experience disproportionate worry about work, health, or relationships. For instance, a person might continuously fear poor health despite normal medical evaluations or...
1.2K
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:27Panic Disorder
1.2K
Panic disorder is an anxiety disorder characterized by recurrent and sudden minutes-long episodes of intense fear, known as panic attacks. These attacks may feel like heart attacks and often happen without warning or a specific cause. They can include symptoms such as rapid heart rate, shortness of breath, chest pain, trembling, sweating, dizziness, and a sense of helplessness. During a panic attack, individuals may feel as though they are experiencing a heart attack or are in a...
1.2K
01:26Anxiolytic Drugs: Overview
1.5K
Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
1.5K
01:15Parkinson's Disease: Overview
2.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.5K